Business description
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to the most demanding requirements. With this focus on offering total solutions, Surmodics’ mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.
Management board & Supervisory board
| CEO |
| Gary R. Maharaj |
| Management board |
| Timothy J. Arens, Charles W. Olson, Gordon S. Weber, Joseph J. Stich, Nusrath Sultana, M.D., Teryl L.W. Sides |
| Supervisory board |
| David R. Dantzker, Gary R. Maharaj, Jose H. Bedoya, Lisa Wipperman Heine, Ronald B. Kalich, Susan E. Knight |
Company data
| Name: |
SurModics Inc. |
| Address: |
9924 West 74th Street,Eden Prairie, MN 55344-3523, USA |
| Phone: |
+1-952-500-7000 |
| Fax: |
+1-952-500-7001 |
| E-mail: |
-
|
| Internet: |
www.surmodics.com |
| Industry: |
Commodities |
| Sector: |
Chemicals |
| Sub sector: |
- |
| End of financial year: |
09-30 |
| Free Float: |
53.30% |
| IPO date: |
- |
Investor relations
| Name: |
Tim Arens |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
ir@surmodics.com
|
